Targeting Huntingtin Expression in Patients with Huntington’s Disease

Authors:

Abstract
Huntington’s disease is an autosomal-dominant neurodegenerative disease caused by CAG trinucleotide repeat expansion in HTT, resulting in a mutant huntingtin protein. IONIS-HTTRx (hereafter, HTTRx) is an antisense oligonucleotide designed to inhibit HTT messenger RNA and thereby reduce concentrations of mutant huntingtin.
Funding Information
  • Ionis Pharmaceuticals
  • F. Hoffmann-La Roche

This publication has 26 references indexed in Scilit: